Compare AGM & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | NEO |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 1999 |
| Metric | AGM | NEO |
|---|---|---|
| Price | $177.59 | $11.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $219.00 | $11.38 |
| AVG Volume (30 Days) | 106.6K | ★ 1.8M |
| Earning Date | 02-19-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 12.85 | N/A |
| EPS | ★ 17.55 | N/A |
| Revenue | $377,946,000.00 | ★ $709,162,000.00 |
| Revenue This Year | $14.80 | $10.89 |
| Revenue Next Year | $9.98 | $9.70 |
| P/E Ratio | $10.40 | ★ N/A |
| Revenue Growth | 8.81 | ★ 10.10 |
| 52 Week Low | $155.00 | $4.72 |
| 52 Week High | $212.24 | $14.73 |
| Indicator | AGM | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 39.92 |
| Support Level | $169.35 | $11.18 |
| Resistance Level | $174.48 | $11.79 |
| Average True Range (ATR) | 4.84 | 0.51 |
| MACD | 1.08 | -0.15 |
| Stochastic Oscillator | 62.74 | 15.94 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.